[{"orgOrder":0,"company":"Springs Rejuvenation","sponsor":"Springs Rejuvenation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"Stem Cell Therapy","moa":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Springs Rejuvenation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Springs Rejuvenation \/ Springs Rejuvenation","highestDevelopmentStatusID":"1","companyTruncated":"Springs Rejuvenation \/ Springs Rejuvenation"}]

Find Clinical Drug Pipeline Developments & Deals by Springs Rejuvenation

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : The combined entity will focus on stem cell therapy, facial rejuvenation, hair rejuvenation, non-surgical hair restoration, protein rich plasma (PRP) injections, and anti-aging treatments.

Product Name : Undisclosed

Product Type : Cell and Gene therapy

Upfront Cash : Undisclosed

December 20, 2021

Lead Product(s) : Stem Cell Therapy

Therapeutic Area : Dermatology

Highest Development Status : Undisclosed

Recipient : Avra

Deal Size : Undisclosed

Deal Type : Merger

blank